Citations

Clear

6273 citation(s) found for "To, Andrew".

Purkinje Cell Cytoplasmic Antibody Type 1 (Anti-Yo) Autoimmunity in a Child With Down Syndrome
Philipps, Guillermo, Alisanski, Susan, Pranzatelli, Michael R. , Clardy, Stacey , Lennon, Vanda A. , McKeon, Andrew , Clardy, Stacey L, McKeon, Andrew , Clardy, Stacey L

Mayo Clinic

JAMA Neurology | January 14, 2014 | Volume: 71 | Issue: 3 | Pages: 347

10.1001/jamaneurol.2013.4551 | PMID 24424854 Get It

International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation
Palumbo, Antonio , Miguel, Jesús F. San , Larocca, Alessandra , Niesvizky, Rubén, Morgan, Gareth J. , Hájek, Roman , Dimopoulos, Meletios Α. , Richardson, Paul G. , Cavo, Michèle , Spencer, Andrew , Stewart, A. Keith, Shimizu, Kazuyuki , Sonneveld, Pieter , Durie, Brian G.M. , Moreau, Philippe , Orlowski, Robert Z. , Rajkumar, S. Vincent , Landgren, Ola , Einsele, Hermann , Anderson, Kenneth C. , Richardson, Paul Gerard Guy , Lonial, Sagar , Orlowski, Robert Z. , Hajek, Roman , Dimopoulos, Meletios A , Moreau, Philippe , San-Miguel, Jesus , Morgan, Gareth J

Mayo Clinic

Journal of Clinical Oncology | January 13, 2014 | Volume: 32 | Issue: 6 | Pages: 587-600

10.1200/jco.2013.48.7934 | PMID 24419113 Get It

Purpose To provide an update on recent advances in the management of patients with multiple myeloma who are not eligible for autologous stem-cell transplantation. Methods A comprehensive review of the literature on diagnostic criteria is provided, and treatment options and management of adverse events are summarized. Results Patients with symptomatic disease and organ damage (ie, hypercalcemia, renal failure, anemia, or bone lesions) require immediate treatment. The International Staging System and chromosomal abnormalities identify high- and standard-risk patients. Proteasome inhibitors, immunomodulatory drugs, corticosteroids, and alkylating agents are the most active agents. The presence of concomitant diseases, frailty, or disability should be assessed and, if present, treated with reduced-dose approaches. Bone disease, renal damage, hematologic toxicities, infections, thromboembolism, and peripheral neuropathy are the most frequent disabling events requiring prompt and active supportive care. Conclusion These recommendations will help clinicians ensure the most appropriate care for patients with myeloma in everyday clinical practice.
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
Richardson, Paul G. , Vij, Ravi , Chen, Christine , Jakubowiak, Andrzej , Song, Kevin , Belch, Andrew , Shustik, Chaim, Lentzsch, Suzanne , Lacy, Martha Q. , Matous, Jeffrey, Vesole, David H. , Chen, Min , Zaki, Mohamed H. , Jacques, Christian , Yu, Zhinuan, Richardson, Paul Gerard Guy , Siegel, David S. , Hofmeister, Craig C. , Baz, Rachid , Jagannath, Sundar , Lonial, Sagar , Bahlis, Nizar Jacques , Raje, Noopur , Mıkhael, Joseph , Anderson, Kenneth C.

Mayo Clinic

Blood | January 13, 2014 | Volume: 123 | Issue: 12 | Pages: 1826-1832

10.1182/blood-2013-11-538835 | PMID 24421329 Get It

Key Points Pomalidomide plus low-dose dexamethasone significantly improved PFS vs pomalidomide alone in relapsed and refractory multiple myeloma. Pomalidomide plus low-dose dexamethasone is an important new treatment option for RRMM patients who have received multiple prior therapies.
High Expression of Somatostatin Receptors and Messenger Ribonucleic Acid for Its Receptor Subtypes in Organ-Confined and Locally Advanced Human Prostate Cancers1
Halmos, Gábor, Davis, Rodney , Bostwick, David G., Płonowski, Artur , Schally, Andrew V. , Sun, Baodong

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | January 8, 2014 | Volume: 85 | Issue: 7 | Pages: 2564-2571

10.1210/jcem.85.7.6698 | PMID 10902809 Get It

To evaluate the potential application of somatostatin (SST) analogs as an adjuvant treatment for prostate cancer, we characterized the binding sites for SST octapeptide analogs on prostate cancers in patients treated with radical prostatectomy. The affinity and density of binding sites for SST analog RC-160 on 80 surgical specimens of prostate cancers were determined by ligand competition assays. The expression of messenger ribonucleic acid (mRNA) for SST receptor subtype 1 (SSTR1), subtype 2 (SSTR2), and subtype 5 (SSTR5) was also investigated in 22 samples by RT-PCR. Fifty-two of 80 specimens (65%), showed a single class of specific binding sites for RC-160 with a mean dissociation constant (Kd) of 9.44 nmol/L and a mean maximal binding capacity of 754.8 fmol/mg membrane protein. The mRNA for SSTR1 was detected in 86% of samples, whereas the incidences of mRNA for SSTR2 and SSTR5 were 14% and 64%, respectively. The expression of SSTR2 and/or SSTR5 was 100%, consistent with the presence of RC-160 binding. In patients at high risk of cancer recurrence (stage pT3 and/or Gleason score of 8–10), the incidence of RC-160 binding (65.7%) was similar to that observed in the low risk group (64.3%). The demonstration of the high incidence of octapeptide-preferring SSTRs in organ-confined and locally advanced prostate cancers supports the merit of further investigations of the application of SST analogs and their radionuclide and cytotoxic derivatives for adjuvant treatment of patients at high risk of cancer recurrence after radical prostatectomy. Such approaches could be also considered for patients with advanced prostate cancer at the time of relapse.
Survey Finds Few Orthopedic Surgeons Know The Costs Of The Devices They Implant
Okike, Kanu , O’Toole, Robert V. , Pollak, Andrew N. , Bishop, Julius A. , McAndrew, Christopher M. , Mehta, Samir, Cross, William W., Garrigues, Grant E. , Lebrun, Christopher , Mehta, Samir, Harris, Mitchel B.

Mayo Clinic

Health Affairs | January 6, 2014 | Volume: 33 | Issue: 1 | Pages: 103-109

10.1377/hlthaff.2013.0453 | PMID 24395941 Get It

Endovascular treatment of acute ischemic stroke: the end or just the beginning?
Khalessi, Alexander A. , Dumont, Travis M., Fessler, Richard D., Ringer, Andrew J. , Veznedaroglu, Erol, Siddiqui, Adnan H. , Hopkins, L. Nelson , Mokin, Maxim , Mocco, J , Lanzino, Giuseppe , Hanel, Ricardó A. , Lopes, Demetrius K. , Bendok, Bernard R. , Levy, Elad I. , Siddiqui, Adnan H

Mayo Clinic

Neurosurgical Focus | January 1, 2014 | Volume: 36 | Issue: 1 | Pages: E5

10.3171/2013.10.focus13374 | PMID 24380482 Get It

Various endovascular intraarterial approaches are available for treating patients with acute ischemic stroke who present with severe neurological deficits. Three recent randomized trials—Interventional Management of Stroke (IMS) III, Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy (MR RESCUE), and Synthesis Expansion: A Randomized Controlled Trial on Intra-Arterial Versus Intravenous Thrombolysis in Acute Ischemic Stroke (SYNTHESIS Expansion)—evaluated the efficacy of endovascular treatment of acute ischemic stroke and, after failing to demonstrate any significant clinical benefit of endovascular therapies, raised concerns and questions in the medical community regarding the future of endovascular treatment for acute ischemic stroke. In this paper, the authors review the evolution of endovascular treatment strategies for the treatment of acute stroke and provide their interpretation of findings and potential limitations of the three recently published randomized trials. The authors discuss the advantage of stent-retriever technology over earlier endovascular approaches and review the current status and future directions of endovascular acute stroke studies based on lessons learned from previous trials.
DNA mismatch repair gene MSH6 implicated in determining age at natural menopause
Perry, John R. B. , Hsu, Yi-Hsiang, Johnson, Andrew D. , Elks, Cathy E., Albrecht, Eva, Andrulis, Irene L. , Berenson, Gerald S., Bojesen, Stig E. , Bolla, Manjeet K. , Brown, Judith, Buring, Julie E. , Campbell, Harry, Chang‐Claude, Jenny , Chenevix‐Trench, Georgia , Corre, Tanguy , Cox, Angela , Czene, Kamila , D’Adamo, Pio , Davies, Gail , Deary, Ian J. , Easton, Douglas F. , Engelhardt, Ellen G. , Eriksson, Johan G. , Fasching, Peter A. , Figueroa, Jonine D. , Flyger, Henrik, Fraser, Abigail , García‐Closas, Montserrat , Gasparini, Paolo , Gieger, Christian , Giles, Graham G. , Guénel, Pascal , Hägg, Sara , Hayward, Caroline , Hopper, John L. , investigators, kConFab, Kardia, Sharon L. R., Kasiman, Katherine, Knight, Julia A. , Lahti, Jari , Lawlor, Debbie A. , Magnusson, Patrik K. E. , Margolin, Sara , Marsh, Julie , Polašek, Ozren , Rahman, Iffat , Ridker, Paul M., Robino, Antonietta , Rudan, Igor , Salumets, Andres , Schmidt, Marjanka K. , Schoemaker, Minouk J. , Smith, Erin N. , Smith, Jennifer A. , Southey, Melissa C. , Stöckl, Doris, Swerdlow, Anthony J. , Thompson, Deborah J. , Truong, Thérèse , Ulivi, Sheila , Waldenberger, Mélanie , Wang, Qin , Wright, Alan F., Zgaga, Lina , Karasik, David , Murray, Anna , Uitterlinden, André G. , Hsu, Yi‐Hsiang , Chasman, Daniel I. , Beesley, Jonathan , Bergmann, Sven M. , Couch, Fergus J. , Dennis, Joe , Esko, Tõnu , Hall, Per N , Ingelsson, Erik , investigators, kConFab, Metspalu, Andres , Olson, Janet E. , Pennell, Craig Edward , Rudolph, Anja , Wild, Sarah H. , Wilson, James Fox , Ong, Ken K. , Murabito, Joanne M. , Giles, Graham G , Swerdlow, Anthony J , Smith, Jennifer A , Southey, Melissa C , Cox, Angela , Guénel, Pascal , García-Closas, Montserrat , Schmidt, Marjanka K , Chenevix-Trench, Georgia , Figueroa, Jonine D , Czene, Kamila , Bojesen, Stig E , Schoemaker, Minouk J , Truong, Therese

Mayo Clinic

Human Molecular Genetics | December 20, 2013 | Volume: 23 | Issue: 9 | Pages: 2490-2497

10.1093/hmg/ddt620 | PMID 24357391 Get It

Investigation of Squeaking in Pyrolytic Carbon Proximal Interphalangeal Joint Implants
Davis, Caleb M. , Thoreson, Andrew R. , Berglund, Lawrence J., Moran, Steven L. , An, Kai‐Nan , Amadio, Peter C.

Mayo Clinic

Journal of Medical Devices | December 19, 2013 | Volume: 8 | Issue: 1 | Pages: No page available

10.1115/1.4026289 Get It

One commonly reported complication of pyrolytic carbon arthroplasty at the proximal interphalangeal (PIP) joint is an annoying, painless, squeaking postoperatively. This squeak has been anecdotally associated with implant loosening or impending dislocation. The purpose of this study was to investigate the etiology of this squeaking. Proximal and distal components of the pyrolytic carbon PIP implant were inserted into foam bones and mounted onto an oscillating test device. We evaluated the effect of 96 combinations of load, velocity, contact angle, implant size, lubrication, and displacement amplitude over a total of 300 cycles for each condition. Sound analysis was performed on squeaking conditions. Fourteen conditions resulted in squeaking, all with a sound pattern similar to that noted clinically. Unlubricated, “dry” joints did not squeak. Squeaking most commonly occurred with fetal bovine serum lubrication, at higher loads, and at 0 deg hyperextension. Hyaluronic acid viscosupplementation stopped the squeaking in all cases.
Short Communication: CD4 T Cell Declines Occurring During Suppressive Antiretroviral Therapy Reflect Continued Production of Casp8p41
Neuhaus, Jacqueline, Sainski, Amy M., Strausbauch, Michael, Wettstein, Peter J., Lewin, Sharon R. , Plana, Montserrat, Rizza, Stacey A. , Temesgen, Zelalem , Touloumi, Giota , Freiberg, Matthew S. , Neaton, James D. , Badley, Andrew D. , Group, for the INSIGHT SMART Study, Cummins, Nathan W. , Plana, Montserrat , Group, for the INSIGHT SMART Study, Badley, Andrew D , Nordwall, Jacqueline

Mayo Clinic

AIDS Research and Human Retroviruses | December 18, 2013 | Volume: 30 | Issue: 5 | Pages: 476-479

10.1089/aid.2013.0243 | PMID 24344953 Get It